Vectis Life Sciences

Vectis Bioscience (formerly known as Vectis Life Sciences) is a biotechnology company specializing in the development of oral delivery solutions for large molecule therapeutics, including peptides, proteins, and monoclonal antibodies. The company's proprietary platform technology is designed to overcome the physiological barriers of the gastrointestinal tract, such as enzymatic degradation and low permeability, enabling the transition from injectable to oral administration. Their primary focus is on developing oral versions of established biologic therapies for chronic inflammatory and autoimmune conditions, with a lead program targeting TNF-alpha for the treatment of inflammatory bowel disease. By improving patient convenience and adherence, Vectis aims to expand the clinical utility and market reach of blockbuster biologics. The company is headquartered in Jersey and maintains research and development operations in the United Kingdom.